Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373513 | 0.87 | KDM1A (0.57) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL22086333 | 0.87 | KDM1A (0.57) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL29116029 | 0.87 | KDM1A (0.57) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL25053373 | 0.87 | KDM1A (0.57) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL27582222 | 0.87 | EPHX2 (0.45) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL17967266 | 0.85 | EPHX2 (0.44) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL25053368 | 0.81 | KDM1A (0.47) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL5241303 | 0.81 | KDM1A (0.55) | KDM1AMAOBEPHX2KMT2AL3MBTL1 | |
| SCHEMBL15716598 | 0.80 | MAPK1 (0.44) | KDM1AMAOBMAPK1 | |
| SCHEMBL27077302 | 0.80 | MAPK1 (0.44) | KDM1AMAOBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | KDM1A 509/4885MAOB 827/4885EPHX2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.